Possible strategies for anti-fibrotic drug intervention in scleroderma

Journal of Cell Communication and Signaling

Volumn 5, Issue 2, 2011, Pages 125-129

  Leask, Andrew ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Endothelin; PDGF; PPAR ; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; DASATINIB; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FIBRONECTIN; IMATINIB; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; ROSIGLITAZONE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; GENETIC TRANSCRIPTION; HUMAN; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS;

EID: 79956356523     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-011-0122-6     Document Type: Review

References (51)

1. A Akhmetshina C Dees M Pileckyte B Maurer R Axmann A Jüngel J Zwerina S Gay G Schett O Distler JH Distler 2008 Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J 22 2214 2222 18326784 10.1096/fj.07-105627 1:CAS:528: DC%2BD1cXotlanurg%3D (Pubitemid 351948641)
2. P Bianco PG Robey I Saggio M Riminucci 2010 "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease Hum Gene Ther 21 1057 1066 20649485 10.1089/hum.2010.136 1:CAS:528:DC%2BC3cXhtFehu7%2FN
3. JC Bonner 2004 Regulation of PDGF and its receptors in fibrotic diseases Cytokine Growth Factor Rev 15 255 273 15207816 10.1016/j.cytogfr.2004.03.006 1:CAS:528:DC%2BD2cXltVKhtL8%3D (Pubitemid 38781050)
4. HA Burgess LE Daugherty TH Thatcher HF Lakatos DM Ray M Redonnet, et al. 2005 PPARγ agonists inhibit TGF-β induced pulmonary myofibroblasts differentiation and collagen production: implications for therapy of lung fibrosis Am J Physiol Lung Cell Mol Physiol 288 L1146 L1153 15734787 10.1152/ajplung.00383.2004 1:CAS:528:DC%2BD2MXlsVylur8%3D (Pubitemid 40695441)
5. Y Chen DJ Abraham X Shi-Wen JD Pearson CM Black KM Lyons A Leask 2004 CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin Mol Biol Cell 15 5635 5646 15371538 10.1091/mbc.E04-06-0490 1:CAS:528:DC%2BD2cXhtVGlsLbI (Pubitemid 39564754)
6. Y Chen X Shiwen J van Beek L Kennedy M McLeod EA Renzoni G Bou-Gharios S Wilcox-Adelman PF Goetinck M Eastwood CM Black DJ Abraham A Leask 2005 Matrix contraction by dermal fibroblasts requires TGFbeta/ALK5, heparan sulfate containing proteoglycans and MEK/ERK: insights into pathological scarring in chronic fibrotic disease Am J Pathol 167 1699 1711 1:CAS:528: DC%2BD28Xkt1arug%3D%3D (Pubitemid 41713321)
7. Y Chen X Shi-wen M Eastwood CM Black CP Denton A Leask DJ Abraham 2006 Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts Arthritis Rheum 54 4 1309 1316 16575856 10.1002/art.21725 1:CAS:528: DC%2BD28XksVyhtbg%3D (Pubitemid 43672944)
8. M Clozel H Salloukh 2005 Role of endothelin in fibrosis and anti-fibrotic potential of bosentan Ann Med 37 2 12 15902842 10.1080/07853890410018925 1:CAS:528:DC%2BD2MXhslenurk%3D (Pubitemid 40347290)
9. CP Denton CM Black DJ Abraham 2006 Mechanisms and consequences of fibrosis in systemic sclerosis Nat Clin Pract Rheumatol 2 134 144 16932673 10.1038/ncprheum0115 (Pubitemid 43771821)
10. CP Denton PA Merkel DE Furst D Khanna P Emery VM Hsu N Silliman J Streisand J Powell A Akesson J Coppock F Hoogen A Herrick MD Mayes D Veale J Haas S Ledbetter JH Korn CM Black JR Seibold Cat-192 Study Group Scleroderma Clinical Trials Consortium 2007 Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum 56 323 333 17195236 10.1002/art.22289 1:CAS:528:DC%2BD2sXhsFaisL8%3D (Pubitemid 46106206)
11. CP Denton JE Pope HH Peter A Gabrielli A Boonstra FH van den Hoogen G Riemekasten S De Vita A Morganti M Dölberg O Berkani L Guillevin TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators 2008 Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases Ann Rheum Dis 67 1222 1228 18055477 10.1136/ard.2007.079921 1:STN:280:DC%2BD1crhtlWhsg%3D%3D
12. G Gabbiani 2003 The myofibroblast in wound healing and fibrocontractive diseases J Pathol 200 500 503 12845617 10.1002/path.1427 1:STN:280: DC%2BD3szhsFOrtg%3D%3D (Pubitemid 36818250)
13. AK Ghosh J Varga 2007 The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis J Cell Physiol 213 663 671 17559085 10.1002/jcp.21162 1:CAS:528:DC%2BD2sXht12jur%2FP (Pubitemid 350058260)
14. AK Ghosh S Bhattacharyya J Wei S Kim Y Barak Y Mori J Varga 2009 Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator FASEB J 23 2968 2977 19395477 10.1096/fj.08-128736 1:CAS:528:DC%2BD1MXhtFagsrjO
15. GR Grotendorst 1997 Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts Cytokine Growth Factor Rev 8 171 179 9462483 10.1016/S1359-6101(97)00010-5 1:CAS:528:DyaK1cXjsVWmsA%3D%3D (Pubitemid 28077925)
16. B Hinz SH Phan VJ Thannickal A Galli ML Bochaton-Piallat G Gabbiani 2007 The myofibroblast: one function, multiple origins Am J Pathol 170 1807 1816 17525249 10.2353/ajpath.2007.070112 1:CAS:528:DC%2BD2sXntlOhtrk%3D (Pubitemid 47339255)
17. A Holmes DJ Abraham S Sa X Shiwen CM Black A Leask 2001 CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling J Biol Chem 276 10594 10601 11152469 10.1074/jbc.M010149200 1:CAS:528: DC%2BD3MXjvFCqtrs%3D (Pubitemid 38089227)
18. W Ishida Y Mori G Lakos L Sun F Shan S Bowes S Josiah WC Lee J Singh LE Ling J Varga 2006 Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo J Invest Dermatol 126 1733 1744 16741519 10.1038/sj.jid.5700303 1:CAS:528:DC%2BD28XmvFantbo%3D (Pubitemid 44086506)
19. M Kapoor M McCann S Liu K Huh CP Denton DJ Abraham A Leask 2009 Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis Arthritis Rheum 60 2822 2829 19714649 10.1002/art.24761 1:CAS:528:DC%2BD1MXht1WhtLfL
20. JH Korn M Mayes M Matucci Cerinic M Rainisio J Pope E Hachulla E Rich P Carpentier J Molitor JR Seibold V Hsu L Guillevin S Chatterjee HH Peter J Coppock A Herrick PA Merkel R Simms CP Denton D Furst N Nguyen M Gaitonde C Black 2004 Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist Arthritis Rheum 50 3985 3993 15593188 10.1002/art.20676 1:CAS:528:DC%2BD2MXls1eguw%3D%3D (Pubitemid 39643947)
21. A Kuhn M Haust V Ruland R Weber P Verde G Felder C Ohmann K Gensch T Ruzicka 2010 Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial Rheumatol Oxford 49 1336 1345 10.1093/rheumatology/keq077 1:CAS:528:DC%2BC3cXnvVygtL4%3D
22. A Leask 2008 Targeting the TGFβ, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma Cell Signal 20 1409 1414 18296024 10.1016/j.cellsig.2008.01.006 1:CAS:528:DC%2BD1cXnsFKkur4%3D
23. A Leask 2009 Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2 J Cell Commun Signal 3 161 162 19475498 10.1007/s12079-009-0056-4
24. A Leask DJ Abraham 2004 TGF-beta signaling and the fibrotic response FASEB J 18 816 827 15117886 10.1096/fj.03-1273rev 1:CAS:528:DC%2BD2cXjvVOnt70%3D (Pubitemid 38544500)
25. A Leask DJ Abraham DR Finlay A Holmes D Pennington X Shi-Wen Y Chen K Venstrom X Dou M Ponticos C Black C Bernabeu JK Jackman PR Findell MK Connolly 2002 Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts Arthritis Rheum 46 1857 1865 12124870 10.1002/art.10333 1:CAS:528:DC%2BD38XmtFWgs7Y%3D (Pubitemid 34774518)
26. A Leask A Holmes CM Black DJ Abraham 2003 Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts J Biol Chem 278 13008 13015 12571253 10.1074/jbc.M210366200 1:CAS:528:DC%2BD3sXislGrt7k%3D (Pubitemid 36800068)
27. A Leask SK Parapuram X Shi-Wen DJ Abraham 2009 Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 3 89 94 19156539 10.1007/s12079-009-0037-7
28. S Liu X Shi-wen L Kennedy D Pala DE Carter CM Black DJ Abraham A Leask 2007 FAK is required for TGFβ-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix remodeling phenotype Mol Biol Cell 18 2169 2178 17409352 10.1091/mbc.E06-12-1121 1:CAS:528:DC%2BD2sXmsVWls74%3D (Pubitemid 46911368)
29. S Liu M Kapoor CP Denton DJ Abraham A Leask 2009 Loss of β1 integrin in mouse fibroblasts results in resistance to a mouse model of skin scleroderma Arthritis Rheum 60 2817 2821 19714619 10.1002/art.24801 1:CAS:528: DC%2BD1MXht1WhtLfJ
30. S Liu R Taghavi A Leask 2010 Connective tissue growth factor is induced in bleomycin-induced skin scleroderma J Cell Commun Signal 4 25 30 19916059 10.1007/s12079-009-0081-3
31. S Liu X Shi-Wen DJ Abraham A Leask 2011 CCN2 is required for bleomycin-induced skin fibrosis Arthritis Rheum 63 239 246 20936632 10.1002/art.30074 1:CAS:528:DC%2BC3MXitVeqtr8%3D
32. T Mori S Kawara M Shinozaki N Hayashi T Kakinuma A Igarashi M Takigawa T Nakanishi K Takehara 1999 Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model J Cell Physiol 181 153 159 10457363 10.1002/(SICI)1097- 4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K 1:CAS:528:DyaK1MXlslWgs7c%3D (Pubitemid 29400382)
33. Y Mori M Hinchcliff M Wu M Warner-Blankenship K Lyons J Varga 2008 Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness Exp Cell Res 314 1094 1104 18201696 10.1016/j.yexcr.2007.12.010 1:CAS:528:DC%2BD1cXisVWjtLc%3D
34. EE Moussad DR Brigstock 2000 Connective tissue growth factor: what's in a name? Mol Genet Metab 71 276 292 11001822 10.1006/mgme.2000.3059 1:CAS:528:DC%2BD3cXms1yjurw%3D
35. J Pannu S Nakerakanti E Smith P ten Dijke M Trojanowska 2007 Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways J Biol Chem 282 10405 10413 17317656 10.1074/jbc.M611742200 1:CAS:528:DC%2BD2sXjs1Siur4%3D (Pubitemid 47093454)
36. SH Park D Saleh A Giaid RP Michel 1997 Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist Am J Respir Crit Care Med 156 2 Pt 1 600 608 9279246 1:STN:280:DyaK2svisFWqtA%3D%3D (Pubitemid 27352001)
37. M Ponticos AM Holmes X Shiwen L Pl K Khan VS Rajkumar RK Hoyles G Bou-Gharios CM Black CP Denton DJ Abraham A Leask GE Lindahl 2009 Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen Arthritis Rheum 60 2142 2155 19565505 10.1002/art.24620 1:CAS:528:DC%2BD1MXptlKrsLw%3D
38. VS Rajkumar C Sundberg DJ Abraham K Rubin CM Black 1999 Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis Arthritis Rheum 42 930 941 10323448 10.1002/1529-0131(199905)42: 5<930::AID-ANR11>3.0.CO;2-1 1:CAS:528:DyaK1MXjtlKjur0%3D (Pubitemid 29215003)
39. VS Rajkumar X Shiwen M Bostrom P Leoni J Muddle M Ivarsson B Gerdin CP Denton G Bou-Gharios CM Black DJ Abraham 2006 Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing Am J Pathol 169 2254 2265 17148686 10.2353/ajpath.2006.060196 1:CAS:528:DC%2BD2sXhvV2nug%3D%3D (Pubitemid 351181983)
40. BL Riser F Najmabadi B Perbal DR Peterson JA Rambow ML Riser E Sukowski H Yeger SC Riser 2009 CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease Am J Pathol 174 1725 1734 19359517 10.2353/ajpath.2009.080241 1:CAS:528:DC%2BD1MXlvVWnu7g%3D
41. C Santander E Brandan 2006 Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway Cell Signal 18 1482 1491 16413747 10.1016/j.cellsig.2005.11.011 1:CAS:528:DC%2BD28Xls1aqtL4%3D (Pubitemid 43832084)
42. JR Seibold CP Denton DE Furst L Guillevin LJ Rubin A Wells M Matucci Cerinic G Riemekasten P Emery H Chadha-Boreham P Charef S Roux CM Black 2010 Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis Arthritis Rheum 62 2101 2108 20506355 10.1002/art.27636 1:CAS:528:DC%2BC3cXht1aqsL3M
43. X Shi-Wen Y Chen CP Denton M Eastwood EA Renzoni G Bou-Gharios JD Pearson M Dashwood RM du Bois CM Black A Leask DJ Abraham 2004 Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts Mol Biol Cell 15 2707 2719 15047866 10.1091/mbc.E03-12-0902 (Pubitemid 38691860)
44. X Shi-wen SL Howat EA Renzoni A Holmes JD Pearson MR Dashwood G Bou-Gharios CP Denton RM du Bois CM Black A Leask DJ Abraham 2004 Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK J Biol Chem 279 23098 23103 10.1074/jbc.M311430200 (Pubitemid 38685614)
45. X Shi-wen F Rodrigues-Pascual S Lamas A Holmes S Howat JD Pearson MR Dashwood RM du Bois CP Denton CM Black DJ Abraham A Leask 2006 Constitutive ALK5-indepenent JNK activation contributes to endothelin-1 over-expression in pulmonary fibrosis Mol Cell Biol 26 5518 5527 16809784 10.1128/MCB.00625-06 (Pubitemid 44036217)
46. X Shi-wen L Stanton L Kennedy D Pala Y Chen SL Howat EA Renzoni DE Carter G Bou-Gharios RJ Stratton JD Pearson F Beier KM Lyons CM Black DJ Abraham A Leask 2006 CCN2 is necessary for adhesive responses to TGF1 in embryonic fibroblasts J Biol Chem 281 10715 10726 16484225 10.1074/jbc.M511343200 (Pubitemid 43855493)
47. X Shi-wen EA Renzoni L Kennedy S Howat Y Chen JD Pearson G Bou-Gharios MR Dashwood RM du Bois CM Black CP Denton DJ Abraham A Leask 2007 Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts Matrix Biol 26 625 632 17681742 10.1016/j.matbio.2007.06. 003 (Pubitemid 350186096)
48. PJ Sime 2008 The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis J Investig Med 56 534 538 18317437 1:CAS:528: DC%2BD1cXivVyjs7Y%3D
49. M Wu DS Melichian E Chang M Warner-Blankenship AK Ghosh J Varga 2009 Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma Am J Pathol 174 519 533 19147827 10.2353/ajpath.2009.080671 1:CAS:528:DC%2BD1MXivVWntrs%3D
50. H Yeger B Perbal 2007 The CCN family of genes: a perspective on CCN biology and therapeutic potential J Cell Commun Signal 1 159 164 18568428 10.1007/s12079-008-0022-6
51. PO Yoon MA Lee H Cha MH Jeong J Kim SP Jang BY Choi D Jeong DK Yang RJ Hajjar WJ Park 2010 The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis J Mol Cell Cardiol 49 294 303 20430035 10.1016/j.yjmcc.2010.04.010 1:CAS:528:DC%2BC3cXntlamsb8%3D